Digital trade protocol for Africa: why it matters, what’s in it and what’s still missing 
EU enlargement: What does the future hold? 
Google Fired Workers Protesting Over Cloud Contract Deal With Israel 
JPMorgan to Leverage AI Across Banking Operations, Jamie Dimon Confirms 
The Original Mouthful: McDonald's Australia Revives Legendary Big Mac Chant with a Tech Twist 
Industry shutdowns are messy and painful: 4 lessons Australia’s coal sector can learn from car-makers about bowing out 
LVMH Adds Bernard Aranault’s Sons Frederic and Alexandre Arnault to the Board 
Samsung's Exynos 2500 Rumored to Eclipse Snapdragon 8 Gen 4 in Power Efficiency With 3nm SoC 
Mentorship is key to improving social and economic outcomes for Black youth 
Be wary of the ‘vibes’: positive investor sentiment doesn’t necessarily match the true value of stocks 
5 Reasons Businesses Can’t Afford Not to Get Fleet Maintenance Software 
Why Africa can be the beating heart of South Korea’s technology industry 
Economists say Australia shouldn’t try to transition to net zero by aping the mammoth US Inflation Reduction Act 
Taxes aren’t just about money – they shape how we think about each other 
McDonald’s Korea Hits Record Revenue Amid Localization and Digital Innovations 
Food prices will climb everywhere as temperatures rise due to climate change – new research 
Eli Lilly, an American pharmaceutical company, headquartered in Indianapolis, Indiana, issued a recall on a batch of its Glucagon Emergency Kits late last month. This is a type of therapy for diabetic patients experiencing an emergency situation.
According to Reuters, it turned out that the recalled emergency kit was manufactured at its factory plant in Indiana. The location is quite controversial because it was cited by the U.S. Food and Drug Administration this year for quality control issues, including substandard sanitation.
The health regulators inspected the said Eli Lilly plant and found violations related to quality control in the manufacturing of some of its products. Thus, with the recall, it was unavoidable for some to think that it may be connected to the unhygienic plant. Then again, there is no proof for this.
At any rate, Eli Lilly issued the voluntary recall on one batch of its Glucagon Emergency Kit on Sept. 25, and the FDA published the notice on Sept. 26. The health regulator indicated “loss of potency” as the reason for the recall. Moreover, Lilly was also said to have issued a recall in Canada as well.
The pharmaceutical firm recalled the said kits after receiving a report involving a patient who experienced seizures even after being injected with the drug. This is said to be a situation that indicates the treatment is not potent enough to provide relief or to work as it should. Based on the report, Eli Lilly said the failure could be due to the manufacturing process, but it did not specify or elaborate what exactly the main issue could be.
The drug is mainly used for the treatment of diabetes patients with dangerously low blood sugar. It was described as an anti-hypoglycemic agent and a gastrointestinal motility inhibitor for the treatment of severe hypoglycemia in patients with diabetes mellitus.
Meanwhile, in response to inquiries about the place of production for the recalled product, Eli Lilly confirmed to Reuters that the affected Glucagon Emergency Kit lots were indeed made at its Indianapolis facility. It added that the recalled drug had been distributed in Canada. Around 66,000 units were affected by the recall, and some 19,000 were distributed in the U.S. and Canada.
